WO2005097174A3 - Uses of a combination of ghrelin and somatotropin for the treatment of cachexia - Google Patents

Uses of a combination of ghrelin and somatotropin for the treatment of cachexia Download PDF

Info

Publication number
WO2005097174A3
WO2005097174A3 PCT/DK2005/000242 DK2005000242W WO2005097174A3 WO 2005097174 A3 WO2005097174 A3 WO 2005097174A3 DK 2005000242 W DK2005000242 W DK 2005000242W WO 2005097174 A3 WO2005097174 A3 WO 2005097174A3
Authority
WO
WIPO (PCT)
Prior art keywords
ghrelin
combination
cachexia
individual
somatotropin
Prior art date
Application number
PCT/DK2005/000242
Other languages
French (fr)
Other versions
WO2005097174A2 (en
Inventor
Birgitte Holst Lange
Claes Post
Olof Gustav Paulus Isaksson
Tina Geritz Nielsen
Original Assignee
Gastrotech Pharma As
Birgitte Holst Lange
Claes Post
Olof Gustav Paulus Isaksson
Tina Geritz Nielsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastrotech Pharma As, Birgitte Holst Lange, Claes Post, Olof Gustav Paulus Isaksson, Tina Geritz Nielsen filed Critical Gastrotech Pharma As
Publication of WO2005097174A2 publication Critical patent/WO2005097174A2/en
Publication of WO2005097174A3 publication Critical patent/WO2005097174A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

The present invention relates to the use of a secretagogue, such as a ghrelin-like compound, in combination with a growth hormone, such as somatotropin or a variant thereof, for the production of a medicament for the treatment of an individual in need thereof, and to a method of treating or preventing cachexia, stimulating appetite, food intake and/or weight gain in an individual in need thereof by administering a ghrelin-like compound. Furthermore, the invention relates to pharmaceutical compositions comprising at least one secretagogue and at least one growth hormone, and medical packagings comprising one or more of said pharmaceutical composition. In another aspect, the present invention relates to a method of treating an individual in need thereof, such as an individual suffering from cachexia, by administering at least one secretagogue, such as a ghrelin-like compound, in combination with at least one growth hormone.
PCT/DK2005/000242 2004-04-07 2005-04-07 Uses of a combination of ghrelin and somatotropin for the treatment of cachexia WO2005097174A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400575 2004-04-07
DKPA200400575 2004-04-07

Publications (2)

Publication Number Publication Date
WO2005097174A2 WO2005097174A2 (en) 2005-10-20
WO2005097174A3 true WO2005097174A3 (en) 2005-12-29

Family

ID=34981400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000242 WO2005097174A2 (en) 2004-04-07 2005-04-07 Uses of a combination of ghrelin and somatotropin for the treatment of cachexia

Country Status (1)

Country Link
WO (1) WO2005097174A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045314A2 (en) * 2004-10-27 2006-05-04 Gastrotech Pharma A/S Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024369A1 (en) * 1995-12-28 1997-07-10 Pfizer Inc. Growth-hormone secretagogues
WO2000012047A2 (en) * 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
WO2000026252A1 (en) * 1998-11-03 2000-05-11 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO2000048623A1 (en) * 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
US20030139348A1 (en) * 1994-11-16 2003-07-24 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO2004032952A1 (en) * 2002-10-10 2004-04-22 Gastrotech Pharma A/S Use of ghrelin for treating malnutrition in gastrectomized individuals
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030139348A1 (en) * 1994-11-16 2003-07-24 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
WO1997024369A1 (en) * 1995-12-28 1997-07-10 Pfizer Inc. Growth-hormone secretagogues
WO2000012047A2 (en) * 1998-09-02 2000-03-09 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
WO2000026252A1 (en) * 1998-11-03 2000-05-11 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO2000048623A1 (en) * 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
WO2004032952A1 (en) * 2002-10-10 2004-04-22 Gastrotech Pharma A/S Use of ghrelin for treating malnutrition in gastrectomized individuals
WO2005014032A2 (en) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; February 2004 (2004-02-01), KOUTKIA, P. ET AL.: "Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy", XP002353699, Database accession no. NLM14559725 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; June 2002 (2002-06-01), SHUTO, Y. ET AL.: "Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity", XP002353700, Database accession no. NLM12045256 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; September 2002 (2002-09-01), YAKAR, S. ET AL.: "Circulating levels of IGF-1 directly regulate bone growth and density", XP002353701, Database accession no. NLM12235108 *

Also Published As

Publication number Publication date
WO2005097174A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
EP3434687A3 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007038506A3 (en) Method for the treatment of cachexia
WO2009129437A3 (en) Methods and compositions for treating post-operative pain comprising clonidine
WO2006032042A3 (en) Us of cntf or a cntf derivative in combination with a further compound for the preparation of medicament for the treatment of obesity
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
MX2010002392A (en) Improved brimonidine compositions for treating erythema.
WO2009020643A3 (en) Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2006045319A3 (en) Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
ZA200703166B (en) Composition comprising lactic acid and lactoferrin
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2006045314A3 (en) Use of a growth hormone secretatogue for increasing or maintaining lean body mass and/or for treatment of chronic obstructive pulmonary disease
WO2007014253A3 (en) Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
WO2009019708A3 (en) Pharmaceutical compositions and methods for the treatment of cancer
HK1098352A1 (en) Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis
WO2005097174A3 (en) Uses of a combination of ghrelin and somatotropin for the treatment of cachexia
WO2005014032A3 (en) Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
WO2006045313A3 (en) Uses of secretagogues for treatment of organ transplant patients
WO2009070564A3 (en) Compositions and methods for prevention of infection in transcutaneous osseointegrated implants
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase